You are now leaving www.klisyrihcp.com
You are now leaving KlisyriHCP.com and will be directed to an independent, third-party website. The Privacy Policy and the Terms of Use of the destination website will apply.
Quick Links
KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Eligible, commercially insured patients whose insurance covers KLISYRI® may pay as little as $25 for the 5-day treatment course. Commercially insured patients who do not have coverage for KLISYRI® may pay as little as $60 at a retail pharmacy or as little as $25 at a pharmacy within the Almirall Advantage Network. Restrictions, terms and conditions apply. Full terms and conditions can be found on www.almiralladvantage.com. Available savings may vary and are subject to maximum reimbursement limits.
Access the KLISYRI® Patient Brochure, a guide for your patients starting treatment.
Access the KLISYRI® Patient Brochure, a guide for your patients starting treatment.
KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of KLISYRI is more likely to result in irritation.
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
To report an adverse event or product complaint, call or email: Medical Affairs and Customer Relations • Phone: 1-866-665-2782 • Fax: 510-595-8183 • Email: almirallmc@eversana.com
KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of KLISYRI is more likely to result in irritation.
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
To report an adverse event or product complaint, call or email: Medical Affairs and Customer Relations • Phone: 1-866-665-2782 • Fax: 510-595-8183 • Email: almirallmc@eversana.com
Reference:
1. Breakaway Partners, May 2022.